Our first experience with utilisation of hydrolytic enzymes in arterior uveitis

Porubská M.

Department of Ophthalmology, Institute of Respiratory Diseases, Nový Smokovec, Slovakia

Slovak abstract.

Summary

Objective: New therapeutic methods with lower adverse effects than those of corticosteroids and immunosuppressive are seeked for in the treatment of anterior uveitis. The aim of the monitoring was assess the efficacy of Wobenzym and Phlogenzym in the anterior uveitis activity and to compare their therapeutic effect with the effect of high doses of both the system and parabulbar application of corticosteroids and/or immunosuppressives.
Methods: A group of 29 hospitalized patients with the high activity of anterior acute and chronic uveitis received enzyme preparations for 8 weeks and paralelly, decrease of inflammatory activity was evaluated.
Results: In a group of patients with anterior acute uveitis mostly associated with ankylosing spondylitis, inflammatory cells from the eye anterior chamber in patients treated with hydrolytic enzymes got absorbed on average in 20 days compared to 27 days in the control group. In the patients with chronic anterior uveitis mostly associated with juvenile chronic arthritis all the inflammatory cells in 50 % of the patients treated with Wobenzym got absorbed on average in 20.3 days, in 60 % of the patients treated with Phlogenzym they got absorbed on average in 17.3 days with the most persisting effect and in the control group in 37 % of 'the patients on average in 30 days. In the patients receiving enzymes. Fibrín and Tyndal got absorbed in 1 day, in the control group in 4-5 days.
Conclusion: The results suggest that, utilization of hydrolytic enzymes makes possible to lower the dosage of corticoids and contributes to shorter time needed for inhibition of the uveitis inflammatory activity, important especially in children with JCA. The best results were observed in administration of Phlogenzym.

Key words: hydrolytic enzymes, corticosteroids, anterior chamber, uveitis.